½ÃÀ庸°í¼­
»óǰÄÚµå
1540805

¼¼°èÀÇ ¸é¿ªÁø´Ü ½ÃÀå º¸°í¼­ : Á¦Ç°, ±â¼ú, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Immunodiagnostics Market Report by Product, Technology, Application, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 146 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¸é¿ªÁø´Ü ½ÃÀå ±Ô¸ð´Â 2023³â 188¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2024-2032³â±îÁö 6.7%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸À̸ç 2032³â±îÁö 343¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

¸é¿ªÁø´ÜÀº Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÌ¿ëÇÏ¿© °¨¿° ¹× ¸¸¼º ÁúȯÀ» °ËÃâÇϴ ü¿Ü Áø´Ü ±â¼úÀÔ´Ï´Ù. ¹æ»ç¼±, Çü±¤, ¹ß»ö È¿¼Ò, ÇÁ·Îºê¸¦ »ç¿ëÇÏ¿© Áúº´ÀÇ ÁøÇàÀ» È®ÀÎÇϱâ À§ÇÑ Ç¥Àû ¹üÀ§ÀÇ È®´ë¸¦ µ½´Â Ç×ü¸¦ È®ÀÎÇÕ´Ï´Ù. ¸é¿ª Áø´ÜÀº È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ÃøÁ¤¹ý, È­ÇÐ ¹ß±¤¹ý, ¹æ»ç¼º ¸é¿ª ºÐ¼®¹ý, ½Å¼Ó °Ë»ç¸¦ À§ÇÑ ´Ù¾çÇÑ ½Ã¾à, ±â±â ¹× ¼ÒÇÁÆ®¿þ¾î ±â¹Ý ¼Ö·ç¼Çµµ »ç¿ëÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, È£Èí±âÁúȯ, ³»ºÐºñÁúȯ, Á¾¾çÁúȯ µîÀÇ Áúº´ Áø´Ü, ¹ýÀÇÇÐ ½É¸®ÇÐ, ȯ°æ ¹× ½Äǰ ºÐ¼® µî¿¡ ³Î¸® Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú, ¸é¿ªÁø´ÜÀº º´¿ø, ÀÓ»ó½ÇÇè½Ç, ¿¬±¸±â°ü, Çмú±â°ü µî ´Ù¾çÇÑ ºÐ¾ß¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

¸é¿ªÁø´Ü ½ÃÀå µ¿Çâ :

´ëÁßµé »çÀÌ¿¡¼­ ¸¸¼º Áúȯ°ú °¨¿°¼º ÁúȯÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ Áúº´¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, BÇü °£¿°, ´ç´¢º´, ¾Ï°ú °°Àº Áúº´¿¡ ´ëÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¸é¿ª Áø´Ü ŰƮ, ºÐ¼®±â ¹× ºÐ¼® Àåºñ ¼ö¿ä¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Â÷¼¼´ë ¸é¿ªÁø´Ü Ç÷§Æû °³¹ß µî ´Ù¾çÇÑ ±â¼ú ¹ßÀüÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ÇöÀåÁø´Ü(POCT) ½Ã½ºÅÛÀº ÆÐÇ÷Áõ, ±Þ¼º ½É±Ù°æ»ö ¹× »ç¸Á·üÀÌ ³ôÀº ±âŸ ÀÇ·á Áúȯ¿¡ ´ëÇÑ Áø´Ü ¿ª·®À» °­È­ÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ½ÅÈï±¹À» Áß½ÉÀ¸·Î ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÇ°í ÀÖÀ¸¸ç, °³ÀÎ ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ´ëÁßÀÇ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ´Â Á¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®µé

  • ¸é¿ªÁø´Ü ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°è ¸é¿ªÁø´Ü ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è ¸é¿ªÁø´Ü ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº?
  • Äڷγª19°¡ ¼¼°è ¸é¿ªÁø´Ü ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è ¸é¿ªÁø´Ü ½ÃÀåÀÇ ¿ëµµº° ½ÃÀå ÇöȲÀº?
  • ¼¼°è ¸é¿ªÁø´Ü ½ÃÀåÀÇ ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ÇöȲÀº?
  • ¼¼°è ¸é¿ªÁø´Ü ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è ¸é¿ªÁø´Ü ½ÃÀåÀÇ ÁÖ¿ä ÁøÃâ ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¸é¿ªÁø´Ü ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ºÐ¼®
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • ½Ã¾à
  • ±â±â
  • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

Á¦7Àå ½ÃÀå ºÐ¼® : ±â¼úº°

  • È¿¼Ò ¸é¿ªÃøÁ¤¹ý
  • È­ÇÐ ¹ß±¤ ¸é¿ªÃøÁ¤¹ý
  • Çü±¤ ¸é¿ªÃøÁ¤
  • ¹æ»ç ¸é¿ªÃøÁ¤
  • ½Å¼Ó ½ÃÇè
  • ±âŸ

Á¦8Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

  • °¨¿°Áõ
  • Á¾¾çÇÐ ¹× ³»ºÐºñÇÐ
  • °£¿° ¹× ·¹Æ®·Î¹ÙÀÌ·¯½º
  • »À ¹× ¹Ì³×¶ö
  • ÀÚ°¡¸é¿ª
  • ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿
  • ±âŸ

Á¦9Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ÀÓ»ó½ÃÇè½Ç
  • Çмú ¿¬±¸¼¾ÅÍ
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö »ê¾÷
  • ±âŸ

Á¦10Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Abbott Laboratories
    • Arkray Inc.
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • DiaSorin S.p.A.
    • F. Hoffmann-La Roche AG
    • Immunodiagnostic Systems Holdings PLC
    • Johnson & Johnson
    • Siemens AG
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.
LSH 24.09.02

The global immunodiagnostics market size reached US$ 18.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 34.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.7% during 2024-2032.

Immunodiagnostics refers to an in-vitro diagnostic technology that uses antigen-antibody reaction for the detection of infectious and chronic diseases. It involves the use of radiological, fluorescent or color-forming enzymes and probes for the identification of antibodies that aid in enhancing the targeting range to identify disease progression. Immunodiagnostics also uses various reagents, instruments and software-based solutions for enzyme-linked immunosorbent assay, chemiluminescence, radioimmunoassay and rapid testing. These solutions are widely used for diagnosing diseases, such as cancer and autoimmune, respiratory, endocrine and oncological disorders, along with forensic psychology and environmental and food analysis. As a result, immunodiagnostics finds extensive applications across hospitals, clinical laboratories and research and academic institutes.

Immunodiagnostics Market Trends:

The increasing prevalence of chronic medical ailments and infections among the masses is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the growth of the market. There is also an escalating awareness among the consumers regarding the available treatment alternatives for ailments, such as hepatitis B, diabetes and cancer, which is positively impacting the demand for immunodiagnostics kits, assays and analyzers. Additionally, various technological advancements, such as the development of next-generation immunodiagnostics platforms, are anticipated to drive the market toward growth. These advanced point-of-care testing (POCT) systems offer enhanced diagnostic facilities for sepsis, acute cardiac infractions and other medical disorders with higher mortality rates. Other factors, including the increasing requirement for personalized medicines among the masses, along with extensive improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global immunodiagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, technology, application and end user.

Breakup by Product:

Reagents

Instruments

Software and Services

Breakup by Technology:

Enzyme-Linked Immunosorbent Assay

Chemiluminescence Immunoassay

Fluorescent Immunoassay

Radioimmunoassay

Rapid Test

Others

Breakup by Application:

Infectious Diseases

Oncology and Endocrinology

Hepatitis and Retrovirus

Bone and Mineral

Autoimmunity

Cardiac Biomarker

Others

Breakup by End User:

Hospitals

Clinical Laboratories

Academic and Research Centers

Pharmaceutical and Biotechnology Industry

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arkray Inc., bioMerieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche AG, Immunodiagnostic Systems Holdings PLC, Johnson & Johnson, Siemens AG, Sysmex Corporation and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1. How big is the global immunodiagnostics market?
  • 2. What is the expected growth rate of the global immunodiagnostics market during 2024-2032?
  • 3. What are the key factors driving the global immunodiagnostics market?
  • 4. What has been the impact of COVID-19 on the global immunodiagnostics market?
  • 5. What is the breakup of the global immunodiagnostics market based on the application?
  • 6. What is the breakup of the global immunodiagnostics market based on the end user?
  • 7. What are the key regions in the global immunodiagnostics market?
  • 8. Who are the key players/companies in the global immunodiagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunodiagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Reagents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software and Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Enzyme-Linked Immunosorbent Assay
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chemiluminescence Immunoassay
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Fluorescent Immunoassay
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Radioimmunoassay
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Rapid Test
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Infectious Diseases
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Oncology and Endocrinology
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Hepatitis and Retrovirus
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Bone and Mineral
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Autoimmunity
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Cardiac Biomarker
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinical Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Academic and Research Centers
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Pharmaceutical and Biotechnology Industry
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Arkray Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 bioMerieux SA
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bio-Rad Laboratories Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 DiaSorin S.p.A.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Immunodiagnostic Systems Holdings PLC
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Johnson & Johnson
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Siemens AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Sysmex Corporation
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦